Skip to main content
News Icon

Publication

Nature Publication by Heneka and colleagues

Inflammatory Processes Drive Progression of Alzheimer's and Other Brain Diseases

Report in "Nature" Inflammation drives the progression of neurodegenerative brain diseases and plays a major role in the accumulation of tau proteins within neurons. An international research team led by Prof. Michael Heneka (DZNE), member of cluster of excellence ImmunoSensation, and the University of Bonn comes to this conclusion in the journal "Nature". The findings are based on the analyses of human brain tissue and further lab studies. In the particular case of Alzheimer's the results reveal a hitherto unknown connection between Abeta and tau pathology. Furthermore, the results indicate that inflammatory processes represent a potential target for future therapies. ies. In the particular case of Alzheimer's the results reveal a hitherto unknown connection between Abeta and tau pathology. Furthermore, the results indicate that inflammatory processes represent a potential target for future therapies.

Publication

NLRP3 inflammasome activation drives tau pathology

Christina Ising et al., Nature (2019), DOI: 10.1038/s41586-019-1769-z

Related news

Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

Publication

Approval of a Novel Retinal Implant Technology

—A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

Publication

The Gut as a Key Player in Immunotherapy for MS

—B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry
Dr. Ivana Jorgacevic und Prof. Dr. Rayk Behrendt have discovered that the inflammatory messenger substance interferon-alpha can trigger Sjögren's syndrome: The researchers in Bonn.

Publication

New test points to precision treatment for autoimmune condition

—Interferon alpha is an inflammatory mediator that can cause Sjögren’s syndrome, an autoimmune disease. This is revealed in a recent study carried out by the University Hospital Bonn together with the University of Bonn, the University of Edinburgh and Newcastle University. Their findings, which have been published in the journal “Lancet Rheumatology,” could make it easier in the medium term to develop drugs to fight this chronic condition.
View entry

Back to the news overview